荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

休市中 07-26 16:08:20

13.900

+0.020

+0.14%

最高14.360	最低13.760	成交量84.05万
今开13.880	昨收13.880	日振幅4.32%
总市值75.66亿	流通市值26.35亿	总股本5.44亿
成交额1,174万	换手率0.44%	流通股本1.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":13.9,"timestamp":1721981300031,"preClose":13.88,"halted":0,"volume":840500,"delay":0,"floatShares":189581239,"shares":544332083,"eps":-3.0056272,"marketStatus":"休市中","marketStatusCode":7,"change":0.02,"latestTime":"07-26 16:08:20","open":13.88,"high":14.36,"low":13.76,"amount":11739450,"amplitude":0.043228,"askPrice":13.96,"askSize":6000,"bidPrice":13.9,"bidSize":3000,"shortable":3,"etf":0,"ttmEps":-3.059639310326791,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"listingDate":1604851200000,"adjPreClose":13.88,"openAndCloseTimeList":[[1721957400000,1721966400000],[1721970000000,1721980800000]],"volumeRatio":0.541559278354005,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":25.16,"timestamp":1721977200000,"preClose":25.33,"halted":0,"volume":3851398,"delay":0,"premium":"-48.53"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2454133714","title":"荣昌生物（688331）7月25日主力资金净卖出541.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454133714","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454133714?lang=zh_cn&edition=full","pubTime":"2024-07-26 08:21","pubTimestamp":1721953309,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年7月25日收盘，荣昌生物报收于25.33元，下跌2.31%，换手率2.32%，成交量3.75万手，成交额9559.1万元。近5日资金流向一览见下表：荣昌生物融资融券信息显示，融资方面，当日融资买入225.77万元，融资偿还150.19万元，融资净买入75.58万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072600012651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","LU2148510915.USD","688331","BK1574","BK0239","BK1161","LU1064131003.USD","LU1969619763.USD","BK1583","LU1064130708.USD","09995"],"gpt_icon":0},{"id":"2454582772","title":"荣昌生物定增拟募资上限调减近6亿元 募投项目不变","url":"https://stock-news.laohu8.com/highlight/detail?id=2454582772","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454582772?lang=zh_cn&edition=full","pubTime":"2024-07-25 19:58","pubTimestamp":1721908687,"startTime":"0","endTime":"0","summary":"“ADC药物第一股”的定增项目有新变动。7月24日晚间，荣昌生物（688331.SH，股价25.33元，市值137.88亿元）发布关于调整公司2024年度向特定对象发行A股股票方案的公告。公司向特定对象发行股票募集资金总额由不超过25.5亿元（含本数）调整至不超过19.53亿元（含本数）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407253140195294.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407253140195294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","09995","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2454822554","title":"持续“烧钱”的荣昌生物：上市至今募资近80亿，商业化“回血”慢难覆盖高昂费用","url":"https://stock-news.laohu8.com/highlight/detail?id=2454822554","media":"钛媒体APP","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454822554?lang=zh_cn&edition=full","pubTime":"2024-07-25 19:52","pubTimestamp":1721908346,"startTime":"0","endTime":"0","summary":"7月25日晚间，荣昌生物（688331.SH/09995.HK）公布了修订后的2024年度向特定对象发行A股股票预案，公司本次定向募集资金总额不超过19.53亿元，拟全部用于新药研发项目。公告称，本次发行股票数量不超过本次发行前公司总股本的13%，即本次发行的股票数量不超过70763170股（含本数）。值得注意的是，这一调减后募资规模较原计...","market":"hk","thumbnail":"https://inews.gtimg.com/om_ls/OtRfq8XZhdl98VzcylASMW77jhPZDyJJHe0KO3L2_H6LMAA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OtRfq8XZhdl98VzcylASMW77jhPZDyJJHe0KO3L2_H6LMAA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20240725A08X6U00","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20240725A08X6U00","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["LU1969619763.USD","BK1574","LU2328871848.SGD","BK1161","BK1583","09995"],"gpt_icon":0},{"id":"2454825218","title":"荣昌生物下调募资金额 定增能跟上“烧钱”速度吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2454825218","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454825218?lang=zh_cn&edition=full","pubTime":"2024-07-25 18:44","pubTimestamp":1721904277,"startTime":"0","endTime":"0","summary":"7月25日，荣昌生物发布关于修订定增预案的公告，将募资额度由25.50亿元降至19.53亿元，募资仍用于公司新药研发项目。自2022年3月登陆科创板以来，荣昌生物一度陷入资金紧张局面，距离登陆科创板时48元/股的发行价，股价几近腰斩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407253140151313.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407253140151313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","09995","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2454898109","title":"股价腰斩后的荣昌生物调低定增融资总额，较原来缩水两成多","url":"https://stock-news.laohu8.com/highlight/detail?id=2454898109","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454898109?lang=zh_cn&edition=full","pubTime":"2024-07-25 10:07","pubTimestamp":1721873245,"startTime":"0","endTime":"0","summary":"近期陷入资金吃紧质疑漩涡的荣昌生物（688331.SH、09995.HK），于7月24日晚间公布了修改后的定增融资方案。公告显示，公司本次拟向特定对象发行股票募集资金总额不超过19.53亿元（含本数）。本次发行对象为不超过三十五名（含三十五名）特定投资者，包括符合中国证监会规定条件的证券投资基金管理公司、证券公司等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202407253139797248.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202407253139797248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","09995","BK1583","BK1574","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2454605198","title":"股价腰斩后的荣昌生物调低定增融资总额，较原来缩水两成多","url":"https://stock-news.laohu8.com/highlight/detail?id=2454605198","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454605198?lang=zh_cn&edition=full","pubTime":"2024-07-25 10:02","pubTimestamp":1721872947,"startTime":"0","endTime":"0","summary":"近期陷入资金吃紧质疑漩涡的荣昌生物，于7月24日晚间公布了修改后的定增融资方案。与公司今年3月29日公布的拟定增募集资金总额不超过25.5亿元相比，本次融资金额缩水了23.41%。截至今年一季度末，荣昌生物账面上的货币资金仅剩下6.23亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251003219ee80996&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407251003219ee80996&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","09995","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","688331"],"gpt_icon":0},{"id":"2454862936","title":"北向资金7月24日净卖出荣昌生物31.32万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2454862936","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454862936?lang=zh_cn&edition=full","pubTime":"2024-07-25 09:30","pubTimestamp":1721871038,"startTime":"0","endTime":"0","summary":"7月24日，北向资金减持荣昌生物31.32万股连续3日减持。截止当日收盘，沪股通共持有荣昌生物376.53万股，占流通股2.32%。沪股通减持金额前五个股分别为贵州茅台、伊利股份、长江电力、中国建筑、工商银行。荣昌生物近5个交易日下跌11.68%，沪股通累计减持33.78万股；近20个交易日下跌45.47%，沪股通累计增持227.01万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407250935449ee7f2fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407250935449ee7f2fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09995","BK1583","BK1574","LU1969619763.USD","688331","LU2328871848.SGD"],"gpt_icon":0},{"id":"2454835895","title":"荣昌生物(09995.HK)调整建议A股发行方案  集资最多19.5亿人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=2454835895","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454835895?lang=zh_cn&edition=full","pubTime":"2024-07-25 01:16","pubTimestamp":1721841360,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布，调整建议A股发行方案，所得款项总额由原先不超过25.5亿人民币，调整至不超过19.53亿人民币，所得净额将全部用于新药研发项目。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-24 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210305144102705_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1366061/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2148510915.USD","688331","399300","159982","09995","BK1161","LU1064130708.USD","LU1064131003.USD","BK1583","LU2328871848.SGD","LU1969619763.USD","BK0239","BK1574"],"gpt_icon":0},{"id":"2453889158","title":"荣昌生物(09995)调减定增募资金额","url":"https://stock-news.laohu8.com/highlight/detail?id=2453889158","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453889158?lang=zh_cn&edition=full","pubTime":"2024-07-24 21:52","pubTimestamp":1721829143,"startTime":"0","endTime":"0","summary":"荣昌生物(09995)公布，于 2024 年 7 月 24 \n日，董事会审议通过《...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_7.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_7.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1155257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1969619763.USD","LU1064131003.USD","09995","BK1583","BK1574","BK0239","688331","LU2328871848.SGD","LU2148510915.USD","BK1161","LU1064130708.USD"],"gpt_icon":0},{"id":"2453486009","title":"荣昌生物：7月24日召开董事会会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2453486009","media":"每日经济新闻","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453486009?lang=zh_cn&edition=full","pubTime":"2024-07-24 20:21","pubTimestamp":1721823702,"startTime":"0","endTime":"0","summary":"每经AI快讯，荣昌生物7月24日晚间发布公告称，公司第二届第十四次董事会会议于2024年7月24日在公司会议室以现场结合通讯方式召开。审议了《关于公司向特定对象发行股票方案的论证分析报告（修订稿）的议案》等。2023年1至12月份，荣昌生物的营业收入构成为：医药制造业占比99.37%。每经头条（nbdtoutiao）——上市公司深陷“内斗”，旗下子公司要“独立”：不认你这控股股东了！没给到约定的资金，还拖欠货款，干扰经营，公司运营产生重大困难(记者 王晓波)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072420220995568282&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072420220995568282&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","LU1064130708.USD","688331","LU1064131003.USD","LU2148510915.USD","09995"],"gpt_icon":0},{"id":"2453028957","title":"荣昌生物盘中异动 急速跳水5.18%报13.921港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453028957","media":"腾讯自选股综合","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453028957?lang=zh_cn&edition=full","pubTime":"2024-07-24 14:10","pubTimestamp":1721801443,"startTime":"0","endTime":"0","summary":"2024年07月24日下午盘13时42分，荣昌生物股票出现异动，股价大幅跳水5.18%。截至发稿，该股报13.921港元/股，成交量133.6万股，换手率0.70%，振幅7.77%。资金方面，该股资金流入405.594万港元，流出1077.6万港元。荣昌生物股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，华康生物医学、正大企业国际、科笛-B涨幅较大，振幅较大的相关个股有华康生物医学、荃信生物-B、盛禾生物-B，振幅分别为20.00%、18.20%、13.18%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2024-07-24/doc-incfffqe7287713.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2024-07-24/doc-incfffqe7287713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","LU1969619763.USD","BK1574","BK1583","LU2328871848.SGD","09995"],"gpt_icon":1},{"id":"2453707166","title":"荣昌生物07月23日遭主力抛售283万元 环比增加732.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453707166","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453707166?lang=zh_cn&edition=full","pubTime":"2024-07-23 16:15","pubTimestamp":1721722533,"startTime":"0","endTime":"0","summary":"07月23日, 荣昌生物股价跌5.29%，报收14.68元，成交金额2486万元，换手率0.89%，振幅7.48%，量比1.21。荣昌生物今日主力资金净流出283万元，连续3日净流出，上一交易日主力净流出34万元，今日环比增加732.35%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为41.67%，平均跌幅为3.60%。该股近5个交易日下跌10.27%，主力资金累计净流出229万元；近20日主力资金累计净流出1160万元，其中净流出天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723161601955262e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240723161601955262e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2328871848.SGD","BK1161","09995","BK1583","BK1574"],"gpt_icon":0},{"id":"1158279501","title":"异动解读 | 荣昌生物旗舰产品泰它西普获批上市 股价大跌5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158279501","media":"异动解读","labels":["movement"],"top":-1,"share":"https://www.laohu8.com/m/news/1158279501?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:32","pubTimestamp":1721716340,"startTime":"0","endTime":"0","summary":"7月22日,荣昌生物(09995)公告称,其旗舰产品泰它西普(商品名:泰爱®)正式获得国家药品监督管理局批准在中国上市,用于治疗中重度活动性类风湿关节炎成人患者。\n\n泰它西普是荣昌生物的核心产品,此前已在欧洲和日本等多个国家和地区获批上市。获得国内上市批准被视为公司的重大利好消息,有望为公司带来新的收入增长点。\n\n然而,就在公告发布当天,荣昌生物股价出现了5.68%的大跌。这一反常走势引发了市场的广泛关注和质疑。分析人士认为,可能是由于投资者对泰它西普在国内市场的销售前景存在疑虑,加之国内医药行业监管趋严,导致公司估值出现下调。不过具体原因仍有待进一步观察和分析。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"gpt_icon":0},{"id":"2453670879","title":"荣昌生物(09995)下跌5.03%，报14.72元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453670879","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453670879?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:18","pubTimestamp":1721715520,"startTime":"0","endTime":"0","summary":"7月23日，荣昌生物(09995)盘中下跌5.03%，截至14:18，报14.72元/股，成交1053.08万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年一季报，荣昌生物营业总收入3.3亿元、净利润-3.49亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/23141841729525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1969619763.USD","LU1064131003.USD","BK0239","BK1583","BK1574","688331","LU1064130708.USD","LU2328871848.SGD","LU2148510915.USD","09995","BK1161"],"gpt_icon":0},{"id":"2453087307","title":"荣昌生物盘中异动 下午盘大幅跳水5.03%报14.721港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453087307","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453087307?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:18","pubTimestamp":1721715515,"startTime":"0","endTime":"0","summary":"2024年07月23日下午盘14时18分，荣昌生物股票出现波动，股价快速下跌5.03%。截至发稿，该股报14.721港元/股，成交量69.95万股，换手率0.37%，振幅6.06%。资金方面，该股资金流入353.942万港元，流出535.114万港元。荣昌生物股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，华康生物医学、盛禾生物-B、荃信生物-B涨幅较大，振幅较大的相关个股有华康生物医学、盛禾生物-B、荃信生物-B，振幅分别为34.69%、12.14%、9.20%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231418359681f394&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407231418359681f394&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","LU1969619763.USD","LU2328871848.SGD","09995","BK1161"],"gpt_icon":0},{"id":"2453703368","title":"荣昌生物(09995)股价下跌5.032%，现价港币$14.72","url":"https://stock-news.laohu8.com/highlight/detail?id=2453703368","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453703368?lang=zh_cn&edition=full","pubTime":"2024-07-23 14:18","pubTimestamp":1721715480,"startTime":"0","endTime":"0","summary":"[下跌股]荣昌生物(09995) 股价在下午02:18比前收市价下跌5.032%，现股价为港币$14.72。至目前为止，今日最高价为$15.66，而最低价为$14.72。总成交量为69.7万股，总成交金额为港币$1.049千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152745608_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407231364/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK0239","688331","LU1064130708.USD","LU1064131003.USD","LU2328871848.SGD","BK1161","LU1969619763.USD","LU2148510915.USD","09995","BK1574","BK1583"],"gpt_icon":0},{"id":"2453747932","title":"智通港股早知道 | 7月份105款游戏获批 美股三大指数集体回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2453747932","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2453747932?lang=zh_cn&edition=full","pubTime":"2024-07-23 07:15","pubTimestamp":1721690150,"startTime":"0","endTime":"0","summary":"纳入后，港股通ETF目前已达到16只。若欧盟最终确定与大众和宝马达成降低税率协议，将是欧盟在对华电动汽车关税问题上的首次实质性妥协。7月份国产网络游戏审批信息公布 共105款游戏获批智通财经APP获悉，7月22日，国家新闻出版署发布2024年7月份国产网络游戏审批信息，共105款游戏获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154211.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1224","TSLA","09992","00511","HSCEI","BK1151","LU2328871848.SGD","BK1161","BK1583","BK1119","09995","BABA","LU1969619763.USD","09863","09866","09699","NVDA","XPEV","BK1145","YANG","HSTECH","BK1574"],"gpt_icon":1},{"id":"2453718721","title":"荣昌生物(09995.HK)泰它西普获批准用于治疗类风湿关节炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2453718721","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453718721?lang=zh_cn&edition=full","pubTime":"2024-07-23 00:51","pubTimestamp":1721667060,"startTime":"0","endTime":"0","summary":"荣昌生物(09995.HK) 公布，泰它西普(商品名：泰爱)正式获得中国国家药品监督管理局在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎成人患者。泰它西普是集团专有用于治疗自身免疫性疾病的新型融合蛋白，产品已于2023年11月正式获得中国国家药品监督管理局在中国的完全上市批准，用于治疗系统性红斑狼疮。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-07-22 16:25。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210305144101571_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210305144101571_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1365404/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688331","09995","LU1064130708.USD","LU1969619763.USD","BK1161","BK0239","BK1574","BK1583","LU1064131003.USD","LU2148510915.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2453279122","title":"港股公告掘金 | 小鹏汽车-W与大众汽车集团签订电子电气架构技术战略合作联合开发协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2453279122","media":"智通财经","labels":["Company Corporation"],"top":-1,"share":"https://www.laohu8.com/m/news/2453279122?lang=zh_cn&edition=full","pubTime":"2024-07-22 22:55","pubTimestamp":1721660156,"startTime":"0","endTime":"0","summary":"【重大事项】：小鹏汽车-W(09868)与大众汽车集团签订电子电气架构技术战略合作联合开发协议北京能源国际(00686)：北京京能拟收购工银投资持有的目标公司的全部股权 涉资约30.2亿元荣昌生物(09995)：泰它西普(商品名：泰爱)获得国药监局完全批准用于治疗类风湿关节炎患者中国安储能源(02399)拟1亿港元收购Rosy Estate Global Limited全部股权的29%思捷环球(0","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","BK1575","HSCEI","LU2328871848.SGD","BK4505","BK1161","BK1153","00686","BK1583","BK1119","09995","BK1539","LU1969619763.USD","BK1610","BK1154","BK4099","BK1588","EVS.SI","SG9999002463.SGD","XPEV","01508","YANG","09868","BK1550","BK4526","BK1554","BK1536","BK1133","BK1594","BK4555","HSTECH","LU0593848301.USD","00762","BK4551","BK1506","BK1587","BK1574"],"gpt_icon":1},{"id":"2453214765","title":"荣昌生物(09995.HK)：泰它西普(商品名：泰爱)获得国家药监局完全批准用于治疗类风湿关节炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2453214765","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453214765?lang=zh_cn&edition=full","pubTime":"2024-07-22 19:22","pubTimestamp":1721647376,"startTime":"0","endTime":"0","summary":"格隆汇7月22日丨荣昌生物公告，泰它西普正式获得中国国家药品监督管理局在中国上市的完全批准，用于与甲氨蝶呤联合治疗针对甲氨蝶呤疗效不佳的中、重度活动性类风湿关节炎成人患者。泰它西普在本适应症获得批准，是基于一项在RA患者中开展的以甲氨蝶呤为基础治疗的随机、双盲、安慰剂对照、多中心的III期临床研究，共入组479例患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072219230695e81c87&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072219230695e81c87&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","09995","BK1583","BK1574","LU2328871848.SGD","BK1161"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.1032},{"period":"1month","weight":-0.4755},{"period":"3month","weight":-0.5443},{"period":"6month","weight":-0.2813},{"period":"1year","weight":-0.6908},{"period":"ytd","weight":-0.6288}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0591},{"period":"3month","weight":-0.0357},{"period":"6month","weight":0.067},{"period":"1year","weight":-0.1333},{"period":"ytd","weight":-0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事创新型生物药研发和制造的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单克隆抗体及双特异性抗体等治疗性抗体药物的发现、开发与商业化。该公司的主要产品包括泰它西普（RC18）、维迪西妥单抗（RC48）和双靶点融合蛋白（RC28）。该公司的产品主要应用于治疗自身免疫疾病、肿瘤和眼科等重大疾病。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.188174},{"month":2,"riseRate":0.75,"avgChangeRate":0.173193},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108046},{"month":4,"riseRate":0.75,"avgChangeRate":-0.020996},{"month":5,"riseRate":0.25,"avgChangeRate":-0.095931},{"month":6,"riseRate":0.75,"avgChangeRate":0.127279},{"month":7,"riseRate":0.5,"avgChangeRate":-0.070932},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.052805},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.023458},{"month":10,"riseRate":0.666667,"avgChangeRate":0.128837},{"month":11,"riseRate":1,"avgChangeRate":0.035442},{"month":12,"riseRate":0.5,"avgChangeRate":0.023444}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}